Viamet develops novel therapies by leveraging its expertise in metalloenzyme chemistry and biology. The company's clinical portfolio focuses on treating chronic and life-threatening fungal infections, with additional research in oncology and orphan diseases. Viamet designs drug candidates to offer improved safety and efficacy profiles compared to existing treatments.
Funding
Funding not disclosed
Founders
Product
Problem
Current treatments for chronic and life-threatening fungal infections often suffer from limitations in safety and efficacy. Existing therapies may not be well-tolerated by patients, and the emergence of drug-resistant fungal strains poses a significant challenge. There is a need for novel therapeutic options that can overcome these limitations and improve patient outcomes.
Solution
Viamet, operating within the Metaverde, LLC innovation hub, is focused on developing novel therapies leveraging metalloenzyme chemistry and biology. The company designs drug candidates with the goal of achieving improved safety and efficacy profiles compared to existing treatments, particularly for chronic and life-threatening fungal infections. Viamet's approach aims to address the limitations of current antifungal therapies and combat the growing problem of drug resistance. While the company's initial focus is on fungal infections, research also extends to oncology and orphan diseases, indicating a broader application of their core technology. By targeting metalloenzymes, Viamet seeks to create more effective and better-tolerated treatments for a range of challenging medical conditions.
Target Audience
The primary target audience includes patients suffering from chronic and life-threatening fungal infections, as well as healthcare providers seeking more effective and safer treatment options.
Features
- Focus on metalloenzyme chemistry and biology for drug development
- Design of drug candidates with improved safety and efficacy profiles
- Clinical portfolio targeting chronic and life-threatening fungal infections
- Research programs in oncology and orphan diseases